FDA Approves Grand Pharmaceutical Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule

Reuters

Jul 07

FDA Approves <a href="https://laohu8.com/S/CGPHF">Grand Pharmaceutical</a> Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule

Grand Pharmaceutical Group Ltd. has announced that the U.S. Food and Drug Administration (FDA) has officially approved a new indication for their globally innovative radioactive product, SIR-Spheres® Y-90 Resin Microsphere Injection, ahead of schedule. This approval marks a significant milestone for the company, enhancing their portfolio of advanced treatment options. Additionally, the Group, in collaboration with Sirtex Medical Pty Limited, Telix Pharmaceuticals Limited, and ITM Isotope Technologies Munich SE, has been involved in establishing a world-class tumor intervention R&D platform. This collaboration highlights the combined efforts of multiple organizations in advancing medical innovation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on July 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2549537129"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549537129\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549537129?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-07 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549537129","market":"us","top_or_hot":-1,"title":"FDA Approves Grand Pharmaceutical Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Approves <a href=\"https://laohu8.com/S/CGPHF\">Grand Pharmaceutical</a> Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Grand Pharmaceutical Group Ltd. has announced that the U.S. Food and Drug Administration (FDA) has officially approved a new indication for their globally innovative radioactive product, SIR-Spheres® Y-90 Resin Microsphere Injection, ahead of schedule. This approval marks a significant milestone for the company, enhancing their portfolio of advanced treatment options. Additionally, the Group, in collaboration with Sirtex Medical Pty Limited, <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> Limited, and ITM Isotope Technologies Munich SE, has been involved in establishing a world-class tumor intervention R&amp;D platform. This collaboration highlights the combined efforts of multiple organizations in advancing medical innovation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on July 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approves Grand Pharmaceutical Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approves Grand Pharmaceutical Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-07 21:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Approves <a href=\"https://laohu8.com/S/CGPHF\">Grand Pharmaceutical</a> Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Grand Pharmaceutical Group Ltd. has announced that the U.S. Food and Drug Administration (FDA) has officially approved a new indication for their globally innovative radioactive product, SIR-Spheres® Y-90 Resin Microsphere Injection, ahead of schedule. This approval marks a significant milestone for the company, enhancing their portfolio of advanced treatment options. Additionally, the Group, in collaboration with Sirtex Medical Pty Limited, <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> Limited, and ITM Isotope Technologies Munich SE, has been involved in establishing a world-class tumor intervention R&amp;D platform. This collaboration highlights the combined efforts of multiple organizations in advancing medical innovation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on July 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00512","symbol_name":"远大医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nNDL8XVgZg:1","article_id":"2549537129","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549537129","pubTimestamp":1751893486,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Grand Pharmaceutical Group Ltd. has announced that the U.S. Food and Drug Administration  has officially approved a new indication for their globally innovative radioactive product, SIR-Spheres Y-90 Resin Microsphere Injection, ahead of schedule. This approval marks a significant milestone for the company, enhancing their portfolio of advanced treatment options. Additionally, the Group, in collaboration with Sirtex Medical Pty Limited, Telix Pharmaceuticals Limited, and ITM Isotope Technologies Munich SE, has been involved in establishing a world-class tumor intervention R&D platform. This collaboration highlights the combined efforts of multiple organizations in advancing medical innovation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00512":"远大医药","BK1191":"制药","TLX.AU":"TELIX PHARMACEUTICALS LTD","BK7067":"生物科技"},"translate_title":"FDA提前批准远大医药集团创新型SIR-Spheres Y-90树脂微球注射液","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":0.9,"TLX.AU":0.9},"content_text":"FDA Approves Grand Pharmaceutical Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule\n    \n\n        Grand Pharmaceutical Group Ltd. has announced that the U.S. Food and Drug Administration (FDA) has officially approved a new indication for their globally innovative radioactive product, SIR-Spheres® Y-90 Resin Microsphere Injection, ahead of schedule. This approval marks a significant milestone for the company, enhancing their portfolio of advanced treatment options. Additionally, the Group, in collaboration with Sirtex Medical Pty Limited, Telix Pharmaceuticals Limited, and ITM Isotope Technologies Munich SE, has been involved in establishing a world-class tumor intervention R&D platform. This collaboration highlights the combined efforts of multiple organizations in advancing medical innovation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on July 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}